

# Right Device for the Right Patient: The Importance of Device Choice in Personalizing COPD Treatment



## **Important Information for Health Care Providers receiving this slide deck**

- This slide deck is being provided in response to your request for a slide presentation regarding the importance of device choice in personalizing COPD treatment.
- This slide deck was prepared and is intended to be presented in its entirety and should not be edited
- You are not speaking on behalf of AstraZeneca and receipt of this deck does not imply that you are
- This deck is for use by the recipient institution or organization, its employees or agents, for medical education purposes only, and should not be forwarded to other third parties
- This deck should not be used for patient education
- This slide deck may contain hyperlinks that are not functional in this format
- The attached slide deck may contain copyright protected work(s):
  - AstraZeneca has obtained permission from the copyright owner to use such work in this presentation
  - You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law

# Objectives

---

- Review goals of COPD treatment and the importance of inhaler device choice
- Discuss characteristics of commonly used delivery devices
- Discuss the importance of training and regular follow-up to ensure proper inhaler use

# Overview of COPD

COPD is a heterogenous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli that cause persistent, often progressive, airflow obstruction<sup>1</sup>

- The characteristic chronic respiratory symptoms of COPD are dyspnea, cough, sputum production and/or exacerbations<sup>1</sup>
- Mucus hypersecretion may be linked to decline in airflow over time<sup>2</sup>
- Dyspnea is a cardinal symptom of COPD<sup>1</sup> and can lead to self-limitation of activity,<sup>3</sup> which, in turn, can lead to further deconditioning and aggravated dyspnea<sup>4</sup>

# Approaches to Treatment

## Goals of Treatment of Stable COPD According to GOLD

- Relieve symptoms
- Improve exercise tolerance
- Improve health status

REDUCE  
SYMPTOMS

+


- Prevent disease progression
- Prevent and treat exacerbations
- Reduce mortality

REDUCE RISK


**A key component of COPD treatment is inhaled medication**  
Rescue and maintenance medications

**Proper inhaler technique training is important to help with proper use of inhalers**

# Device Choice Is an Important Part of Management



# Consider Differences in Delivery Mechanisms When Choosing an Inhalation Device



- Randomized controlled trials have not identified superiority of one device or formulation<sup>1</sup>
- A survey of 513 HCPs showed that in newly diagnosed patients only about 1/3 considered the device to be highly important when prescribing medication<sup>2</sup>
- It is important to consider the characteristics of each device when selecting medication(s) for patients with COPD

Adapted from: National Jewish Health. Devices for inhaled medications (asthma inhalers, COPD inhalers). March 29, 2018. National Jewish Health website.  
<https://www.nationaljewish.org/conditions/medications/asthma-medications/devices>



# Proper Use of a Device Is Critical

“Management of chronic airways disease is 10% medication and 90% education”<sup>1</sup>

- Regardless of inhalation device type, correct use is required for proper delivery<sup>1</sup>
- Observational studies have shown:
  - Errors in device use are common<sup>2,3</sup>
  - Critical errors, which substantially affect dose delivery to the lungs, occurred up to 47% of the time depending on device<sup>2</sup>
  - A significant relationship between improper inhaler use and symptom control in patients with COPD<sup>4</sup>
  - Improper inhaler use has been associated with increased risk of hospitalization and emergency room visits<sup>4</sup>

**Inhaler misuse has been associated with<sup>4</sup>:**

- Older age
- Lower education level
- Lack of instruction from HCPs

# Common Technique Errors With pMDIs and DPIs

Patients often report they use good techniques even when error rates are high<sup>1</sup>  
Patients may not realize they are committing technique errors<sup>2</sup>

## Common errors<sup>3</sup>

### DPI

- No full expiration before inhalation
- No post-inhalation breath hold
- Incorrect device preparation
- Speed and/or depth of inhalation (should be *fast* and deep)

### pMDI

- No full expiration before inhalation
- No post-inhalation breath hold
- Coordination of actuation and inhalation
- Speed and/or depth of inhalation (should be *slow* and deep)

# The Education Gap Around Inhalation Devices

Many patients rely on their primary care physicians for disease education<sup>1</sup>

Healthcare providers may not be proficient in device use<sup>2</sup>


- Physicians and nurses may not receive formal training with inhaler technique, and if trained, may lose proficiency over time<sup>3,4</sup>
- In a survey of pulmonologists and fellows, while they reported knowledge of treatment devices, a minor proportion of respondents reported being very knowledgeable in teaching patients how to use, clean, or maintain the devices<sup>5</sup>
- In a recent survey, 10% of physicians felt fully competent in teaching inhaler use to their patients<sup>2</sup>

A meta-analysis showed that patients often do not receive any device training or retraining<sup>5,6</sup>

- Lack of training regarding device use has been suggested as the primary reason that patients use their devices incorrectly<sup>6</sup>
- Patients who received training usually received it at initial prescription and did not receive any additional follow-up training or further assessment of inhaler technique<sup>6</sup>

# Training Can Reduce Device Errors


## Basics of Effective Training Include:



- Technique improved significantly after step-by-step training, tailored to device type
- Face-to-face training improved technique

# Device Consistency Can Be Helpful for Effective Use<sup>1,2</sup>

---

- 
- **Operating techniques vary across and within device types**
  - **Device consistency between rescue inhaler and maintenance inhaler can be beneficial in patients with COPD or asthma**

# Choosing a Device: Considerations

## Peak Inspiratory Flow

DPIs have different resistances that impact inhalation flow requirements<sup>1,2</sup>

Minimal PIFR<sub>resist</sub> of a DPI to achieve clinical effect<sup>3</sup>

**PIF ≥30 L/min**

Optimal PIFR<sub>resist</sub> to generate more particles in respirable range<sup>3</sup>

**PIF ≥60 L/min**

The ability to generate sufficient PIF for effective DPI use may be compromised in some patients with COPD:

- The elderly,<sup>1,2</sup> especially those with short stature, female gender, and lower lung volume<sup>3</sup>
- With increasing disease severity<sup>4</sup>
- Hospitalized for acute exacerbation of COPD<sup>5</sup>

1. Janssens W et al. *Eur Respir J*. 2008;31:78-83; 2. Jarvis S et al. *Age Ageing*. 2007;36:213-218; 3. Mahler DA et al. *J Aerosol Med Pulm Drug Deliv*. 2013;26:174-179;

4. Prime D et al. *J Aerosol Med Pulm Drug Deliv*. 2015;28:486-497; 5. Loh CH et al. *Ann Am Thorac Soc*. 2017;14:1305-1311.

# Choosing a Device: Additional Considerations

## Physical and Cognitive Capabilities

### Key Capabilities<sup>1</sup>

Physical ability to load, prime, and actuate device

Cognitive competency


### Comorbidities that may impact key capabilities<sup>1</sup>

- Osteoarthritis and rheumatoid arthritis
- Neurologic conditions
- Impaired sight or hearing

- Dementia/memory impairment
- Stroke
- Depression

**Consider the availability of a reliable caregiver to assist with device setup, administration, cleaning, etc<sup>2</sup>**

# A Proposed Inhaler Decision Tree\*




\*Treatments are not presented in order of preference.  
Dekhuijzen PN et al. *Respir Med.* 2013;107:1817-1821.

# Incorporating Patient Preferences into Device Selection

Device preference, familiarity, and satisfaction can have a significant impact on disease management<sup>1</sup>

From a global\* survey of device preferences in patients with COPD, the following were most important to the patient<sup>2</sup>

Patient preferences of inhalation devices are not always aligned with physician preferences<sup>3</sup>



\*United Kingdom, United States, France, Germany.

1. Virchow JC et al. *J Mark Access Health Policy*. 2015;3:28760; 2. Molimard M et al. *J Aerosol Med Pulm Drug Deliv*. 2015;28:219-228; 3. Roche N et al. *J Aerosol Med Pulm Drug Deliv*. 2017;30:1-13.

# Summary Points

---

**Device choice is an important part of COPD management and should be individually tailored**

**It is important to consider the characteristics of each delivery mechanism when choosing a device**

**Patient factors such as ability and preference can help guide device selection**

**Errors in device use are common; so training and reassessment of technique is critical**

**It is important to provide the right device for the patient to optimize the personalization of COPD management**

- AstraZeneca is committed to conducting business with the highest standards of integrity and professionalism
- If you have any comments about this presentation, please contact AstraZeneca at 1-800-236-9933
- Thank you for your participation today. This concludes today's program

To find scientifically balanced, evidence-based information about AstraZeneca drugs and other medical resources...

Visit  
**AZmedical.com**  
Today



Created by AstraZeneca healthcare professionals for healthcare professionals

# Appendix

# Select Characteristics of Commonly Used Delivery Devices

	Advantages	Disadvantages
pMDI	<ul style="list-style-type: none"> <li>• High reproducibility between doses<sup>1</sup></li> <li>• Independent of inspiratory flow rate<sup>2</sup></li> <li>• Option for spacer add-on<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Actuation required (finger/hand strength)<sup>3,4</sup></li> <li>• Requires coordination of actuation and inhalation<sup>1</sup></li> <li>• High oropharyngeal deposition<sup>5</sup></li> </ul>
pMDI + spacer	<ul style="list-style-type: none"> <li>• Can be used in patients who have difficulty performing adequate pMDI technique<sup>6</sup></li> <li>• Decreased oropharyngeal deposition<sup>5</sup></li> <li>• Can be used with a facemask<sup>6</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Subject to static charge<sup>5</sup></li> <li>• Less portable than pMDI<sup>5</sup></li> <li>• Use with a facemask reduces lung delivery<sup>6</sup></li> </ul>
DPI	<ul style="list-style-type: none"> <li>• Have inspiratory flow signals in some devices<sup>7</sup></li> <li>• Less coordination needed<sup>5</sup></li> <li>• Breath-actuated<sup>3,4,7-9</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Requires minimum inspiratory flow for most devices<sup>3,4,7-9</sup></li> <li>• Loss of dose if patient exhales through device<sup>9</sup></li> <li>• May be sensitive to moisture and humidity<sup>2,7,9</sup></li> </ul>
SMI	<ul style="list-style-type: none"> <li>• Independent of inspiratory flow rate<sup>5</sup></li> <li>• High lung deposition<sup>5</sup></li> <li>• High fine particle fraction<sup>10</sup></li> </ul>	<ul style="list-style-type: none"> <li>• May require complex dose loading assembly<sup>2</sup></li> <li>• Requires press and breathe technique<sup>10</sup></li> <li>• Not breath-actuated<sup>10</sup></li> </ul>
Nebulizer	<ul style="list-style-type: none"> <li>• May be used for any age<sup>5</sup></li> <li>• No specific inhalation technique required<sup>5</sup></li> <li>• May disperse drugs not available with pMDIs and DPIs<sup>5</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Treatment times can be long<sup>5</sup></li> <li>• Performance varies among nebulizers<sup>5</sup></li> <li>• Less portable than inhalers<sup>3,4,9</sup></li> </ul>

1. Chrystyn H et al. *Prim Care Respir J.* 2009;18:243-249; 2. Bonini M et al. *COPD Res Pract.* 2015;1:9; 3. Dolovich MB et al. *Chest.* 2005;127:335-371; 4. Fromer L et al. *Postgrad Med.* 2010;122:83-93; 5. Lavorini F. *ISRN Allergy.* 2013;2013:102418; 6. Lavorini F et al. *Expert Opin Drug Deliv.* 2009;6:91-102; 7. Barrons R et al. *Am J Health Syst Pharm.* 2011;68:1221-1232; 8. Geller DE. *Respir Care.* 2005;50:1313-1321; 9. Dolovich MB et al. *Lancet.* 2011;377:1032-1045; 10. Newman SP. *Eur Respir Rev.* 2005;14:102-108.

